Phase 2 N=294 Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
Intracerebral Hemorrhage
Primary: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days — 48; 47 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF)
Cervical Spine
Primary: Percentage of Patients Reporting Dysphagia/Severe Dysphagia Through EAT-10 From Baseline Through 1 Year Post-Op — 9.52; 16.00; 10.34; 0 percentage
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
N/A N=91 Topical Antibiotic Treatment for Spine Surgical Site Infection
Surgical Wound Infection
Primary: Surgeon Attitudes About Using Intra-wound Antibiotics for Spine Surgery — 9; 36; 46 Participants
Phase 2 N=185 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16 — 35.7; 57.1; 61.9; 59.0 percentage of participants — p=0.007
N/A N=184 Understanding Non-Response in Spine Fusion Surgery
Spine Fusion
Primary: Oswestry Disability Index — 41.3; 30.4; 19.4 score on a scale
Phase 3 N=81 G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
Insulin Hypoglycemia · Type 1 Diabetes Mellitus · Severe Hypoglycemia
Primary: Number of Subjects With a Positive Glucose Response — 76; 78 Participants
Phase 2 N=51 TRial on the Endocrine Activity of Neoadjuvant Degarelix
Breast Cancer Invasive Nos
Primary: Time to Optimal Ovarian Function Suppression — 14; 3 days
N/A N=10 Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis
Multiple Sclerosis
Primary: Speed in the Timed 25 Feet Walk Test at Self-selected Speed (Without Exoskeleton) — 0.35 meters per second (m/s)
Phase 2 N=118 A Study LY2228820 for Recurrent Ovarian Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
N/A N=20 Immediate Effects of rTMS on Excitability of the Quadriceps With Knee Osteoarthritis
Osteoarthritis, Knee
Primary: Quadriceps Central Activation Ratio (CAR) — 86.3554; 86.1983; -1.2496; -1.2670 % activation — p=.9994
Phase 4 N=42 Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.
Muscle Relaxation
Primary: Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen — 5.7; 8.29; 6.58 mmHg
Phase 2 N=10 Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) — -42095.14; -49065.88; -32947.50; -33149.13 Copies per milliliter
N/A N=27 Qualitative Analysis of Subject Experience of Nasal Polyps
Nasal Polyps
Primary: Number of Participants Who Reported Primary Symptoms — 27; 27; 25; 24 Participants
Phase 2 N=16 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
B-Cell Prolymphocytic Leukemia · Hypodiploidy · Loss of Chromosome 17p
Primary: Event-Free Survival (EFS) — 9 Participants